HRMY - NASDAQ

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.10

+0.91%

HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.86B

EPS2.7600

P/E Ratio11.63

Earnings Date08/04/2026

hrmy

Selling, General and Administrative Expenses

Last Annual Value

272.05M

3-Year CAGR

19%

5-Year CAGR

23%

10-Year CAGR

25%

Adjust for Inflation

Harmony Biosciences Holdings, Inc. Competitors Analysis of Selling, General and Administrative Expenses

HRMY · NASDAQ

Company	Selling, General and Administrative Expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Harmony Biosciences Holdings, Inc. NASDAQ:HRMY	272.05M	12.2%	15.6%	N/A
MannKind Corporation NASDAQ:MNKD	144.13M	15.2%	13.2%	11.9%
Biohaven Ltd. NYSE:BHVN	106.17M	19.1%	23.2%	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	28.72M	43.6%	N/A	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	43.80M	12.3%	16.4%	2.0%
Janux Therapeutics, Inc. NASDAQ:JANX	41.77M	16.9%	32.2%	N/A
Nuvation Bio Inc. NYSE:NUVB	151.56M	74.5%	44.2%	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	100.22M	61.5%	53.1%	N/A

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.1, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $32.1

Related Guides

Blog Categories

Continue your HRMY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.